Share this article
NEW YORK and GRENOBLE, France, Feb. 2, 2021 /PRNewswire/
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant
in vitro cellular models for cell-based assays in oncology.
Cell&Soft Logo
Existing
in vitro models lack physiological relevance, yielding misleading and non-translatable results that slow essential progress needed to develop effective drugs capable of preventing thousands of cancer deaths each year.